Nasal Polyp Removal — Cost, Top Hospitals & Success Rates | MyMedicPlus

Nasal polyps are benign, grape-like outgrowths of the nasal mucosa arising predominantly from the ethmoid sinuses. They occur almost exclusively in the context of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) — a persistent inflammatory disease of the nasal and sinus mucosa driven by type 2 inflammation (eosinophil activation, elevated IgE, and IL-4/IL-5/IL-13 cytokine excess). CRSwNP affects 2–4% of the general adult population and is strongly associated with adult-onset asthma, aspirin-exacerbated respiratory disease (AERD/Samter's triad), and allergic fungal rhinosinusitis (AFRS).

Patients experience progressive nasal obstruction, loss of smell (anosmia — the most consistent and debilitating symptom), nasal discharge, facial pressure, and sleep disruption. Unlike rhinitis, CRSwNP symptoms typically do not remit spontaneously and worsen over years without active treatment.

Management follows the EPOS 2020 (European Position Paper on Rhinosinusitis and Nasal Polyps, 2020) evidence-based step-up guideline, which integrates medical therapy with surgery and, for severe refractory disease, targeted biologic therapy.

CRSwNP encompasses several overlapping clinical phenotypes:

Eosinophilic CRSwNP (Most Common)

Accounts for 80–85% of CRSwNP in Western populations. Characterised by tissue eosinophilia (>10 eosinophils per high-power field on histology), elevated serum IgE, and frequent comorbid asthma. Associated biomarkers include peripheral blood eosinophilia (>0.25 × 10⁹/L), elevated serum periostin, and high fractional exhaled nitric oxide (FeNO >25 ppb).

Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad)

CRSwNP + asthma + aspirin/NSAID-precipitated respiratory reactions (bronchoconstriction, rhinorrhoea, flushing). COX-1 inhibition diverts arachidonic acid to leukotriene synthesis, causing acute bronchoconstriction and nasal congestion within 30–180 minutes of aspirin ingestion. AERD patients have particularly severe polyposis and high surgical recurrence rates; aspirin desensitisation post-FESS is a specific management strategy.

Allergic Fungal Rhinosinusitis (AFRS)

Type 2 inflammatory response to non-invasive fungal (most commonly Aspergillus, Bipolaris, or Curvularia) colonisation of the sinuses. Characterised by unilateral or asymmetric disease, eosinophilic mucin (dense, peanut-butter-like material in the sinuses), and elevated total IgE with specific IgE/IgG to fungal allergens. Requires surgical clearance of fungal mucin plus long-term topical steroid and antifungal therapy.

Non-Eosinophilic CRSwNP

Accounts for approximately 15–20% of cases; more common in East Asian populations. Characterised by neutrophilic infiltration, lower asthma comorbidity, and potentially different treatment response to biologics.

Surgery is considered after failure of adequate medical therapy per the EPOS 2020 step-up algorithm:

EPOS 2020 Step-Up Algorithm — Summary

1. Step 1: Intranasal corticosteroid (INCS) spray (e.g., mometasone, fluticasone furoate) at full dose for ≥12 weeks. If inadequate — advance.
2. Step 2: Add high-volume nasal saline irrigation (240 mL per side, twice daily). If inadequate — advance.
3. Step 3: Short-course oral corticosteroids (prednisolone 30–40 mg/day × 5–7 days) as a 'rescue' treatment for acute exacerbations or to assess steroid responsiveness. If symptoms recur rapidly — consider surgery.
4. Step 4 — Surgery (FESS): Indicated when symptoms remain uncontrolled after adequate Steps 1–3 and endoscopic/CT confirmation of polyp burden. Surgery clears the obstructed ostiomeatal complex, facilitates topical drug delivery, and restores mucosal drainage.
5. Step 5 — Biologics: For patients with severe, refractory CRSwNP (NPS ≥5, significant impact on quality of life) who have had prior FESS or are unfit for surgery.

Surgical Candidacy

• Confirmed CRSwNP on nasal endoscopy (bilateral middle meatal polyps) and CT sinus (Lund-Mackay score ≥4)
• Failed adequate medical therapy (as above)
• No absolute contraindications to general anaesthesia
• Normal coagulation studies (stop anticoagulants per specific drug bridging guidelines)
• Smoked cannabis within 1 month — airway concerns; discuss with anaesthesia team

1. Functional Endoscopic Sinus Surgery (FESS)

FESS is performed under general anaesthesia, typically as a day case (same-day discharge). Key steps include:

• Polypectomy: Polyps are removed from the nasal cavity and sinuses using a powered microdebrider (rotating cutting blade with simultaneous suction) or through-cutting forceps. The microdebrider is faster and provides better haemostasis than simple forceps avulsion.
• Uncinectomy and antrostomy: Removal of the uncinate process and opening of the maxillary sinus ostium to the size of approximately 1 cm, restoring natural drainage.
• Anterior ethmoidectomy: Opening of the anterior ethmoid air cells (including the ethmoid bulla) that harbour the source polyps.
• Posterior ethmoidectomy and sphenoidotomy: Extended where posterior ethmoid or sphenoid disease is present.
• Frontal sinus procedures (Draf classification):
  • Draf I: Infundibulotomy — removal of agger nasi and anterior ethmoid cells to expose the frontal recess
  • Draf IIa: Widening of the frontal ostium medial to the middle turbinate
  • Draf IIb: Complete ipsilateral frontal sinusotomy from lamina papyracea to the middle turbinate
  • Draf III (Modified Lothrop): Bilateral removal of the entire frontal sinus floor and intersinus septum creating a single large drainage corridor — the 'Frontal T' procedure, reserved for refractory frontal sinus disease

Intra-operative image-guided navigation (electromagnetic or optical CT-linked navigation systems) is recommended for revision surgery, patients with prior surgery-altered anatomy, or when operating near the skull base/orbit.

2. Biologic Therapies (Type 2 Inflammation Targeted)

Biologic treatments specifically target the type 2 inflammatory cascade driving CRSwNP:

• Dupilumab (Dupixent, IL-4Rα blocker — blocks IL-4 and IL-13): The most robustly studied biologic for CRSwNP. In the Phase 3 SINUS-24 and SINUS-52 trials, dupilumab 300 mg subcutaneously every 2 weeks produced a 57% reduction in Nasal Polyp Score (NPS) vs. 6% with placebo, and significantly improved SNOT-22, Lund-Kennedy score, loss of smell, and CT opacification. Approved by FDA (2019), EMA, and most major regulators for severe CRSwNP with or without prior FESS.
• Mepolizumab (Nucala, anti-IL-5): Reduces eosinophil survival. Approved for severe CRSwNP in adults with eosinophilic phenotype (SYNAPSE trial — 27% NPS reduction vs. placebo). Monthly subcutaneous injection.
• Omalizumab (Xolair, anti-IgE): Approved for CRSwNP in adults. POLYP 1 and POLYP 2 trials showed significant NPS reduction vs. placebo in IgE-elevated patients. Dosing varies by body weight and baseline IgE level.
• Benralizumab (Fasenra, anti-IL-5Rα): Approved in some jurisdictions for CRSwNP with comorbid eosinophilic asthma. Achieves near-complete eosinophil depletion.

Biologics are given indefinitely or for a defined trial period (typically 16–52 weeks) with endoscopic and patient-reported outcome assessment. They are not curative — polyps recur when treatment stops.

3. Intranasal and Systemic Corticosteroids

High-potency intranasal steroids (mometasone furoate, fluticasone furoate, budesonide) reduce polyp volume and improve symptoms with long-term use. High-volume budesonide irrigation (1 mg in 240 mL saline per side, twice daily) delivers steroid directly into opened sinus cavities post-FESS. Short courses of oral prednisolone (the 'medical polypectomy') rapidly shrink polyps but have systemic side-effects with repeated use.

4. Aspirin Desensitisation (for AERD)

Following FESS in AERD patients, aspirin desensitisation involves a graded supervised challenge increasing from 30 mg to 325–650 mg/day over 2–3 days. Maintenance aspirin 325–650 mg twice daily significantly reduces polyp recurrence and sinonasal symptom burden in AERD, likely through COX-1 tolerance and leukotriene pathway reset.

• Symptom resolution: FESS achieves significant improvement in nasal obstruction (80–90% of patients), facial pressure, and quality of life scores (SNOT-22) that are maintained at 5 years in the majority
• Smell restoration: FESS improves or restores olfaction in approximately 60–70% of patients with pre-operative anosmia, particularly with concurrent budesonide irrigation; dupilumab achieves similar or superior smell recovery
• Asthma improvement: Treating CRSwNP with FESS or dupilumab reduces asthma exacerbation frequency and oral corticosteroid requirement — reflecting the unified airway disease concept
• Improved topical drug delivery: FESS opens obstructed sinus cavities, allowing nasal saline and steroid irrigation to penetrate the ethmoid and frontal sinuses, dramatically improving post-operative medical therapy efficacy
• Biologic outcomes: Dupilumab achieves a level of polyp control (NPS reduction, smell restoration, CT improvement) that exceeds what FESS alone achieves in many severe-disease patients, without surgical risk
• Day-case surgery: FESS is performed under general anaesthesia and patients are typically discharged on the same day; return to work in 7–14 days

FESS Surgical Risks

• Bleeding (intra-operative): Average blood loss 50–200 mL; transfusion needed in <1% of cases. Pre-operative cessation of antiplatelet agents and the use of local anaesthetic with adrenaline infiltration minimises bleeding.
• Orbital complications: The lamina papyracea (the thin paper-like bone forming the medial orbital wall) borders the ethmoid sinuses. Injury can cause orbital fat herniation (0.5–1%), or — rarely — orbital haematoma (<0.1%) requiring lateral canthotomy decompression. Vision loss is exceedingly rare (<0.01%) in experienced hands.
• Skull base / CSF leak: The ethmoid roof (fovea ethmoidalis) is adjacent to the cribriform plate. Inadvertent injury can cause cerebrospinal fluid (CSF) leak (0.1–0.5%), which requires surgical repair if it does not close spontaneously.
• Anosmia: Paradoxically, injury to the olfactory mucosa at the ethmoid roof can cause permanent olfactory loss. Image-guided surgery and experienced surgeons minimise this risk.
• Synechia (adhesion formation): Post-operative adhesions between the middle turbinate and lateral nasal wall can obstruct the middle meatus. Regular post-operative debridement and septal spacers reduce this risk.
• Infection: Post-operative sinusitis or orbital cellulitis — uncommon with prophylactic antibiotics and nasal irrigation.

Biologic Therapy Risks

• Injection site reactions: Erythema, pain, or pruritus at injection site — most common adverse effect of dupilumab (<10%)
• Conjunctivitis: Occurs in 10–30% of patients on dupilumab (more common in atopic dermatitis cohorts); usually mild and responsive to topical treatment
• Cost: Biologics typically cost $25,000–$40,000 per year; insurance prior authorisation is usually required

Recurrence

Despite excellent short-term outcomes, polyp recurrence is the defining challenge of CRSwNP management. Approximately 30–40% of patients have polyp recurrence requiring revision surgery or biologic therapy at 10 years post-FESS. Risk factors for recurrence include AERD, severe eosinophilia, asthma, pre-operative anosmia, extensive disease, and prior revision surgery.

Immediate Post-Operative Care (FESS)

• Nasal packing: Many surgeons no longer use post-operative nasal packing routinely; haemostatic sealants (e.g., FloSeal) are used intra-operatively instead
• Saline irrigation: High-volume isotonic or hypertonic saline nasal irrigation (240 mL per side, twice daily) begins on day 1–2 post-surgery. This is the single most evidence-based post-operative intervention and must be continued for at least 6–12 months
• Topical steroids: Intranasal steroid spray (and post-FESS steroid irrigation in opened cavities) resumed after 2–4 weeks once early crusting has resolved
• Nasal debridement: Clinic visit at 1 week for endoscopic suctioning of blood clots, crusts, and early synechiae. Repeat at 4–6 weeks.

Follow-Up Schedule

• 1 week: Debridement clinic
• 4–6 weeks: Wound healing assessment, commence steroid irrigation
• 3 months: Assess symptom response; if persistent disease — add or optimise INCS irrigation, consider short oral steroid course
• 6–12 months: Determine need for biologic referral if adequate response not achieved
• Annual endoscopic surveillance indefinitely for CRSwNP (high recurrence risk)

Biologic Monitoring

Patients on dupilumab or other biologics have the NPS assessed endoscopically every 12–16 weeks to document response. Treatment is continued if clinically significant improvement is maintained. Patient-reported outcomes (SNOT-22, VAS nasal obstruction, VAS loss of smell) are tracked at each visit.

Nasal polyp treatment costs span a wide range depending on the modality, setting, and country:

Cost factors for FESS:

• Disease extent: bilateral vs. unilateral; extent of ethmoidectomy required; frontal sinus involvement (Draf III adds significantly to cost and complexity)
• Revision vs. primary surgery (revision adds 20–40% due to altered anatomy and navigation requirements)
• Image-guided navigation system use ($500–$1,500 additional)
• Whether polypectomy is standalone or combined with septoplasty/turbinoplasty

Medical tourism for FESS is growing; India and Thailand offer comparable outcomes to Western centres in JCI-accredited hospitals at 15–30% of UK/US cost. Biologics remain costly globally, though dupilumab biosimilars are anticipated within the next 3–5 years.

• High-dose intranasal steroid alone: Mometasone furoate 200 mcg per nostril twice daily, or fluticasone furoate, can shrink small polyps and maintain disease control in mild-moderate CRSwNP without FESS. Response should be assessed at 12 weeks.
• High-volume corticosteroid nasal irrigation: Budesonide 0.5–1 mg or betamethasone 0.1% in 240 mL saline per side, twice daily, delivers high-dose steroid to the sinus mucosa. Studies show reduction in polyp volume comparable to short oral steroid courses in post-FESS patients.
• Oral corticosteroid 'medical polypectomy': A short course of prednisolone (0.5 mg/kg/day × 5–7 days) can rapidly reduce polyp bulk and restore smell for 4–12 weeks. Not appropriate for long-term or frequent use due to systemic side-effects (glucose, bone density, HPA axis suppression).
• Antileukotriene therapy (montelukast): May have modest adjunctive benefit in aspirin-sensitive patients and those with allergic rhinitis comorbidity; not a replacement for primary therapy.
• Immunotherapy (allergen desensitisation): Subcutaneous or sublingual allergen immunotherapy addresses the atopic trigger in allergic CRSwNP; does not directly treat polyps but may reduce inflammatory drive and improve overall airway control.
• Traditional Chinese medicine / nasal lavage: Some traditional preparations have anti-inflammatory properties; evidence for CRSwNP-specific polyp reduction is limited and these are not recommended as alternatives to evidence-based therapy in EPOS 2020.